ONC:NASDAQ
BeOne Medicines AG
354,27 $
arrow_upward
+2,24%(+7,76) 1D
14 қыр., 14:34:37 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
354,44 $
High
356,00 $
Low
351,92 $
Mkt. cap
41,77 млрд
Avg. vol.
402,48 м.
Volume
122,17 м.
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,51
Shares outstanding
109,79 млн
No. of employees
12 мың
Open
354,44 $
High
356,00 $
Low
351,92 $
Mkt. cap
41,77 млрд
Avg. vol.
402,48 м.
Volume
122,17 м.
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,51
Shares outstanding
109,79 млн
No. of employees
12 мың
News stories
From web sources and news partners
Investing.com
·
2 сағат бұрын
BeOne Medicines at Morgan Stanley conference: brukinsa, pipeline drive growth
TipRanks
·
9 сағат бұрын
BeOne Medicines Reports Strong Employee Uptake of Discounted Share Purchase Plan
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 мың
Founded2010 ж. 28 қаз.
Headquarters-
Sector-
Websitebeonemedicines.com